Personalized leave-behind · per HCP

The one-pager Sarah leaves behind.

After every detail call, Sarah generates a leave-behind tailored to the HCP — drawing from the approved corpus, anchoring every claim to PM section, threading the mandatory ISI. Adjust the inputs on the left and the document on the right re-renders live. Production deployments emit this as PDF; the public demo shows the styled HTML.

Kye Pharma · Health Canada-approved
ACCRUFER
ferric maltol · 30 mg twice daily, oral
Prepared for
Dr. Patel, MD, FRCPC
Hematology · BC

Indication

ACCRUFER is indicated in adults for the treatment of iron deficiency anemia (IDA). For full indication and limitations of use, refer to the approved Product Monograph. — Health Canada PM § 1

AEGIS-IBD subgroup analysis

  • AEGIS-IBD enrolled adults with IDA secondary to quiescent or mildly active IBD intolerant to oral ferrous salts.

    AEGIS-IBD · PM § 14.3

  • Mean Hb increase versus placebo through Week 12 within the IBD population; tolerability profile consistent with the broader program.

    AEGIS-IBD primary endpoint · PM § 14.3

  • GI tolerability remained acceptable in patients with prior intolerance to ferrous salts — the population enriched for the IBD subgroup.

    AEGIS-IBD safety summary · PM § 14.3

Important safety information

  • Contraindications: hypersensitivity to ferric maltol, hemochromatosis or other iron-overload syndromes, repeated blood transfusions.
  • Most common adverse reactions (≥3%): flatulence, diarrhea, constipation, faeces discoloured, abdominal pain/discomfort, nausea.
  • Use in special populations: safety and efficacy not established in patients under 18. Use in pregnancy or breastfeeding only when benefit outweighs potential risk.
  • For full prescribing information, see the Health Canada Product Monograph.

Coverage · BC

For current listing status under BC PharmaCare, please consult the provincial formulary or contact our reimbursement specialist. Coverage may differ for private insurance, NIHB beneficiaries, and Veterans Affairs Canada.

From your rep

Thanks for your time today — leaving this behind as we discussed. Happy to set up an MSL call on the IDA-IBD subgroup whenever useful.

How this fits into Sarah's day

See the Sarah's day timeline — the 08:03 event (“Drafts follow-up to Dr. Patel with the AEGIS-IBD subgroup PDF attached”) is the one-pager pattern. Sarah identifies the right content from the conversation context, generates a personalized version, and queues it for outbound delivery once MLR-approved.

See it in Sarah's day →Talk to Sarah